Article
Early results show antibody fragment beneficial for wet AMD
Author(s):
New York-Treatment with ranibizumab (Lucentis, Genentech) resulted in stable or im-proved vision in 97.5% of patients with wet age-related macular degeneration (AMD) over 6 months, according to the phase Ib/II trial results. Forty-five percent had more than a three-line gain in vision, said Jeffrey S. Heier, MD, a principal investigator in the clinical trial, who reported results at the annual meeting of the American Society of Retina Specialists.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
